HomeAMGN34 • BVMF
add
Amgen Inc. BDR
Nakaraang pagsara
R$54.36
Sakop ng araw
R$54.29 - R$55.50
Sakop ng taon
R$52.10 - R$74.33
Market cap
149.01B USD
Average na Volume
361.00
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 8.15B | 9.43% |
Gastos sa pagpapatakbo | 3.20B | 0.47% |
Net na kita | 1.73B | 1,630.97% |
Net profit margin | 21.23 | 1,496.71% |
Kita sa bawat share | 4.90 | 23.74% |
EBITDA | 3.52B | 19.29% |
Aktuwal na % ng binabayarang buwis | 12.32% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 8.81B | -9.25% |
Kabuuang asset | 89.37B | -3.89% |
Kabuuang sagutin | 83.16B | -5.45% |
Kabuuang equity | 6.21B | — |
Natitirang share | 537.71M | — |
Presyo para makapag-book | 4.71 | — |
Return on assets | 6.46% | — |
Return on capital | 8.98% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 1.73B | 1,630.97% |
Cash mula sa mga operasyon | 1.39B | 101.89% |
Cash mula sa pag-invest | -447.00M | -105.99% |
Cash mula sa financing | -4.11B | -140.46% |
Net change in cash | -3.16B | -155.91% |
Malayang cash flow | 1.21B | -34.48% |
Tungkol
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp Wikipedia
Itinatag
Abr 8, 1980
Headquarters
Website
Mga Empleyado
28,000
